Cost-Effectiveness Analysis of Pembrolizumab as an Adjuvant Treatment of Resected Stage IIB or IIC Melanoma in the United States

被引：0
|
作者：
Shujing Zhang
Arielle G. Bensimon
Ruifeng Xu
Ruixuan Jiang
Alexandra Greatsinger
Adina Zhang
Mizuho Fukunaga-Kalabis
Clemens Krepler
机构：
[1] Merck & Co.,
[2] Inc.,undefined
[3] Analysis Group,undefined
[4] Inc.,undefined
来源：
Advances in Therapy | 2023年 / 40卷
关键词：
Adjuvant treatment; Cost-effectiveness analysis; Pembrolizumab; Stage IIB–IIC melanoma; US health sector perspective;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3038 / 3055
页数：17
相关论文
共 50 条
  • [31] A cost-effectiveness analysis of folic acid fortification policy in the United States
    Bentley, Tanya G. K.
    Weinstein, Milton C.
    Willett, Walter C.
    Kuntz, Karen M.
    PUBLIC HEALTH NUTRITION, 2009, 12 (04) : 455 - 467
  • [32] Cost-Effectiveness Analysis of Sequential Treatment Strategies for Advanced Melanoma in Real Life in France
    Kandel, Marguerite
    Bardet, Aurelie
    Dalle, Stephane
    Allayous, Clara
    Mortier, Laurent
    Guillot, Bernard
    Dutriaux, Caroline
    Leccia, Marie-Therese
    Dalac, Sophie
    Montaudie, Henri
    Saiag, Philippe
    Legoupil, Delphine
    Brunet-Possenti, Florence
    Arnault, Jean-Philippe
    Quatrebarbes, Julie De
    Beylot-Barry, Marie
    Maubec, Eve
    Lesimple, Thierry
    Aubin, Francois
    Grob, Jean-Jacques
    Granel-Brocard, Florence
    Stoebner, Pierre-Emmanuel
    Dupuy, Alain
    Dreno, Brigitte
    Michiels, Stefan
    Lebbe, Celeste
    Borget, Isabelle
    CURRENT ONCOLOGY, 2022, 29 (12) : 9255 - 9270
  • [33] What will it take to make cost-effectiveness analysis acceptable in the United States?
    Luce, BR
    MEDICAL CARE, 2005, 43 (07) : 44 - 48
  • [34] First-line pembrolizumab plus chemotherapy for extensive-stage small-cell lung cancer: a United States-based cost-effectiveness analysis
    Zhu, Youwen
    Hu, Huabin
    Ding, Dong
    Li, Shuosha
    Liao, Mengting
    Shi, Yin
    Huang, Jin
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2021, 19 (01)
  • [35] The cost-effectiveness of male HPV vaccination in the United States
    Chesson, Harrell W.
    Ekwueme, Donatus U.
    Saraiya, Mona
    Dunne, Eileen F.
    Markowitz, Lauri E.
    VACCINE, 2011, 29 (46) : 8443 - 8450
  • [36] First-line pembrolizumab plus chemotherapy for extensive-stage small-cell lung cancer: a United States-based cost-effectiveness analysis
    Youwen Zhu
    Huabin Hu
    Dong Ding
    Shuosha Li
    Mengting Liao
    Yin Shi
    Jin Huang
    Cost Effectiveness and Resource Allocation, 19
  • [37] Cost-effectiveness of first-line enfortumab vedotin in addition to pembrolizumab for metastatic urothelial carcinoma in the United States
    Li, Andong
    Wu, Meiyu
    Xie, Ouyang
    Xiang, Heng
    Meng, Kehui
    Tan, Chongqing
    Wang, Long
    Wan, Xiaomin
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [38] Cost-effectiveness of pembrolizumab versus docetaxel for the treatment of previously treated PD-L1 positive advanced NSCLC patients in the United States
    Huang, Min
    Lou, Yanyan
    Pellissier, James
    Burke, Thomas
    Liu, Frank Xiaoqing
    Xu, Ruifeng
    Velcheti, Vamsidhar
    JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (02) : 140 - 150
  • [39] Cost-effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer in the United States
    Aguiar-Ibanez, Raquel
    Hardern, Chloe
    van Hees, Frank
    Lee, Dawn
    Patel, Anubhav
    Chhabra, Nitika
    Baluni, Gargi
    Amonkar, Mayur
    Lai, Yizhen
    Xu, Ruifeng
    Massaad, Rachid
    Fogelman, David
    JOURNAL OF MEDICAL ECONOMICS, 2022, 25 (01) : 469 - 480
  • [40] Cost-effectiveness of the anti-fibrotics for the treatment of idiopathic pulmonary fibrosis in the United States
    Timothy M. Dempsey
    Viengneesee Thao
    James P. Moriarty
    Bijan J. Borah
    Andrew H. Limper
    BMC Pulmonary Medicine, 22
12345